(Reuters) - The sale of a minority stake in French veterinary health company Ceva Sante Animale is set to attract bids from several buyout groups, three people familiar with the situation said.
Ceva, the ninth-largest animal health group globally with sales of more than 600 million euros, may be valued in total at about 1.4 billion-1.5 billion euros $1.9 billion (1.1 billion pounds)-$2.0 billion or 12-13 times its earnings before interest, taxes, depreciation and amortisation of 116 million euros, one of the sources said.
The sources did not specify the size of the stake involved in the sale. Banking sources said in December that bankers were preparing leveraged debt financing of up to 700 million euros.
"Ceva is a successful company that is preparing its future," a company spokesman said.
Ceva's Chief Executive Marc Prikazsky has said in the past that the current ownership structure is set to end between mid-2014 and mid-2015.
Ceva was originally part of Sanofi-Aventis
In 2007, management and employees acquired a majority stake, and Euromezzanine and Natixis took a minority stake, backed with 433 million euros of loans, according to Thomson Reuters LPC data. Sagard joined as a minority shareholder in 2010.
Ceva focuses on the research, development, production and marketing of pharmaceutical products and vaccines for pets, livestock, pigs and poultry.
Lazard is organising the sale, the sources said.
BC Partners, Charterhouse, Hellman & Friedman and Lazard declined to comment, while Cinven, CVC and KKR were not immediately available for comment.
(Reporting by Arno Schuetze and Claire Ruckin; Editing by Anthony Barker)